Grace Therapeutics

GRCEPhase 3

San Diego, United StatesFounded 2019gracetherapeutics.com

Grace Therapeutics is dedicated to transforming the treatment landscape for patients with severe neurological conditions through innovative science. The company's core strategy involves targeting validated pathways with novel mechanisms of action to improve efficacy and safety profiles. With a lead asset in mid-stage clinical trials and a strong leadership team with deep industry experience, Grace is positioned to generate critical proof-of-concept data. The company's public listing provides a foundation for funding its development programs and pursuing strategic growth.

Market Cap

$62.4M

Founded

2019

Employees

11-50

Focus

Biotech

GRCE · Stock Price

USD 4.422.96 (-40.11%)

Historical price data

AI Company Overview

Technology Platform

Proprietary platform for designing selective small molecule modulators of neuronal ion channels to treat hyperexcitability disorders of the central nervous system.

Pipeline Snapshot

8 drugs in pipeline, 3 in Phase 3

Drug	Indication	Stage
CaPre + Placebo	Hypertriglyceridemia	Phase 3
CaPre + Placebo	Hypertriglyceridemia	Phase 3
GTX-104 + Nimotop 30 MG Oral Capsule	Aneurysmal Subarachnoid Hemorrhage (aSAH)	Phase 3
Lipid Lowering Medication	Hypertriglyceridemia	Phase 2
CaPre (TM) + CaPre (TM)	Hypertriglyceridemia	Phase 2

Opportunities

Significant unmet need in treatment-resistant and rare epilepsies supports premium pricing and expedited pathways.

Positive clinical data could enable expansion into larger neurological indications like neuropathic pain or broader epilepsy segments.

Potential for strategic partnership or acquisition by a larger neurology-focused pharma company.

Risk Factors

High risk of clinical trial failure in Phase 2/3 for lead neurology candidates.

Dependence on capital markets for funding as a pre-revenue company.

Intense competition from both large pharma and other biotechs in the CNS space.

Competitive Landscape

Competes with large pharma (UCB, Eisai) and biotech firms (Marinus, Xenon) in epilepsy. Key differentiation is the targeted selectivity of its ion channel modulators, aiming for better efficacy and tolerability. Must demonstrate clear clinical superiority in well-defined patient populations to succeed.